Abstract: Provided herein are methods for the production of activated CD26high T cells by co-stimulation with inducible coactivator (ICOS). Further provided are methods for treatment of cancer by administration of the of activated CD26high T cells as an adoptive T cell therapy.

Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

Abstract: Disclosed is a composition for selective enrichment of progressively motile non-fragmented/intact DNA sperms during swim-up of semen sample comprising combination of electrolytes, a mix of excipients, polyyvinylpyrrolidone, recombinant human serum albumin or bovine serum albumin. A method of selective enrichment of DNA-intact sperms using the compositions of the present invention is also disclosed. The DNA fragmentation index of the swim-up sperms are less than the DNA fragmentation index of the neat samples. The media compositions of the present invention are applicable for enrichment of non-fragmented/intact DNA sperms for therapeutic purposes in the field of assisted reproductive technologies.

Abstract: A liquid for cryopreserving a cell and a liquid for administration of a mammalian cell capable of cryopreserving a mammalian cell and effectively suppressing cell death after thawing, and a method for cryopreserving a mammalian cell using the cell cryopreservation liquid. The liquid is an isotonic solution that includes 2.0 to 6.0% (w/v) of trehalose or a derivative thereof, or a salt of the trehalose or the derivative, 4.0 to 7.0% (w/v) of dextran or a derivative thereof, or a salt of the dextran or the derivative, and DMSO or glycerin.

Abstract: The present invention provides a fluidic chip for cell culture use which can prevent a decrease in the activity of cultured cells in a preparation stage, and which makes it possible to observe a cultured cell tissue while detaching the cultured cell tissue from the fluidic chip.

Abstract: Disclosed are methods of preparing hematopoietic stem cells and progenitor cells (HSPCs) for transplant into a subject and to methods of using the treated cells. More particularly, methods of the invention comprise treating HSPCs ex vivo with an effective amount of a GABBR1 agonist and administering the treated HSPCs to the subject.

Abstract: This invention relates to variants of Cas12a nucleases having altered protospacer adjacent motif recognition specificity. The invention further relates to methods of making CRISPR-CAS nuclease variants and methods of modifying nucleic acids using the variants.

Abstract: The present invention relates to components, systems, and methods transcriptional modification (e.g., transcriptional activation) or methods of identifying transcriptional effectors based on Cas9-transcription effector fusion protein and gRNA sequence targeting.

Abstract: Disclosed herein are methods for generating mature cardiomyocytes and compositions including mature cardiomyocytes. Also disclosed herein are methods for enhancing maturation of quiescent cardiomyocytes and compositions including mature quiescent cardiomyocytes.

Abstract: Provided is a method for more efficiently sorting out genetically modified cells. Specifically provided are a method for selecting a cell including a modified gene on a target locus in a genome, a method for producing a cell including a modified gene on a target locus in a genome, and an animal including a modified gene on a target locus in a genome, and a kit for selecting an animal including a modified gene on a target locus in a genome and cells including a modified gene on a target locus in a genome.

Abstract: A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGH1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i (to III); i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGIF-?) inhibitor.

Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Abstract: A method of producing renal progenitor cells from pluripotent stem cells involves culturing pluripotent stem cells in a medium containing FGF2, BMP4, a GSK-3? inhibitor, and retinoic acid or a derivative thereof, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, and BMP7, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, BMP7, and a TGF? inhibitor, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, BMP7, activin, and a ROCK (Rho-kinase) inhibitor, culturing the resulting cells in a medium containing retinoic acid or a derivative thereof, and FGF9, and culturing the resulting cells in a medium containing a GSK-3? inhibitor and FGF9, to induce renal progenitor cells from intermediate mesodermal cells.

Abstract: A hanging drop device is provided in the present disclosure. The hanging drop device includes a hanging drop box and a negative pressure module. The hanging drop box includes a plate and a cover. The cover is coupled with the plate to jointly delimit a pressure chamber. The cover includes an upper surface and a bottom surface, a plurality of wells are recessed from the upper surface, and each of the wells is communicated with the pressure chamber through a hole. The negative pressure module is communicated with the pressure chamber. Each of the wells is for containing a liquid, the negative pressure module is for generating a negative pressure in the pressure chamber, so as to drive the liquid in each of the wells to pass through the hole, and the liquid forms a hanging drop hanging from the bottom surface of the cover.

Abstract: Disclosed are means, methods, and compositions of matter useful for treatment of neuroinflammation, autoimmunity, transplant rejection, or graft versus host disease (GVHD) comprising exposing autologous immune cells to allogeneic amniotic fluid derived stem cells. In one embodiment peripheral blood mononuclear cells are cultured in the presence of amniotic fluid stem cells in the presence of interleukin-2 for a period of time sufficient to endow tolerogenic properties. Said tolerogenic properties include ability to suppress adaptive or innate immune responses. In another embodiment the invention provides methods of generating antigen specific immune regulatory cells by culture of lymphocytes together with amniotic fluid stem cells in the presence of antigen to which specific immune regulation is desired.

Abstract: Disclosed are a medium composition for culturing mesenchymal stem cells for the treatment of cancer which can inhibit proliferation of cancer cells, while maintaining differentiation capability and activity thereof, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition. More particularly, disclosed are a medium composition containing vitamin C and aspirin for producing mesenchymal stem cells having improved inhibitory activity against proliferation of cancer cells, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition.

Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.

Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.

Abstract: A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGH1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i (to III); i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGIF-?) inhibitor.

Abstract: A method of applying heat to living tissue mainly uses a device for performing heat treatment on at least a portion of the living tissue in high-low-high temperature steps. In high temperature step, the temperature of the at least a portion of the living tissue is heated and kept between 39-46° C., and the heating period is no longer than 30 minutes. In low temperature step, the at least a portion of the living tissue is cooled, and the low temperature period should not be greater than a natural cooling time interval. In addition, the low temperature period must also be shorter than the heating period. Thus, the present invention allows the abnormal cells to be selectively restored or apoptotic without damaging the normal cells.